Trial Profile
A double-blind placebo-controlled randomised trial of oral sodium clodronate [clodronic acid] for metastatic prostate adenocarcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Sep 2009
Price :
$35
*
At a glance
- Drugs Clodronic acid (Primary)
- Indications Cancer metastases; Prostate cancer
- Focus Therapeutic Use
- 22 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
- 01 Sep 2009 Long-term overall survival results published in Lancet Oncology.
- 29 Sep 2006 Status change